EAM
CEROW

Exos Asset Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Exos Asset Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,700
Closed -$74 – 88
2024
Q2 		$74 Hold
3,700
– – ﹤0.01% 144
2024
Q1 		$252 Buy
+3,700
New +$225 ﹤0.01% 177

Other funds holding CEROW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Exos Asset Management's CEROW Position: Q3 2024 in Review

Exos Asset Management sold out of CERo Therapeutics Warrants (CEROW) in Q3 2024, closing a stake of 3,700 shares — an estimated $74 sold.

Exos Asset Management first reported a position in CEROW in Q1 2024 and held it in 2 quarters. The position peaked at $252 in Q1 2024. 30 funds tracked by Wall St. Rank hold CEROW as of Q3 2024.

  • Exos Asset Management reported no remaining CERo Therapeutics Warrants position as of Q3 2024 after selling out during the quarter.
  • Exos Asset Management sold 3,700 CERo Therapeutics Warrants shares in Q3 2024, an estimated $74.
  • Exos Asset Management first reported a position in CERo Therapeutics Warrants in Q1 2024 and held it in 2 quarters.
  • Exos Asset Management's CERo Therapeutics Warrants position peaked at $252 in Q1 2024.
  • 30 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q3 2024.

Based on Exos Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.